EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Real‐World Overall Survival With Abiraterone Acetate and Enzalutamide in Patients With Chemotherapy‐Naïve Metastatic Castration‐Resistant Prostate Cancer From the Flatiron Electronic Health Records Database

Daniel J George iD, Jasmina I Ivanova, Maëlys Touya, Betty Thompson, Jonathan Assayag, Benjamin Li, Nikolaos Kountouris, Gordon Siu, Stephen J Freedland iD

Cancer Medicine · 2026

DOI: 10.1002/cam4.72356 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Cancer Medicine, 2026. Verfasst von Daniel J George und 8 weiteren Autor:innen. Beteiligte Einrichtung: Duke Cancer Institute, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Abiraterone Acetate, Antineoplastic Combined Chemotherapy Protocols, Benzamides, Nitriles. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Astellas Pharma US, Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with chemotherapy‐ and androgen receptor pathway inhibitor (ARPI)‐naïve metastatic castration‐resistant prostate cancer (mCRPC) have generally shown worse overall survival (OS) with abiraterone versus enzalutamide in claims database studies. Given limitations of claims data, analysis using detailed electronic health records (EHRs) is needed to confirm this finding.

Methods

This EHR‐based analysis (2014–2023) of the Flatiron Health database included patients with chemotherapy‐ and ARPI‐naïve mCRPC who initiated first‐line ARPI (abiraterone or enzalutamide). OS, treatment duration, and time to subsequent therapy were assessed. A subgroup analysis evaluated patients who received first‐line ARPI only with no subsequent treatments. Kaplan–Meier method and Cox proportional hazards models evaluated time‐to‐event outcomes. Stabilized inverse probability treatment weighting (sIPTW) adjusted for baseline differences.

Results

Among 2731 patients, 1316 received first‐line abiraterone and 1415 enzalutamide (median follow‐up: 21.8 and 23.2 months, respectively). sIPTW‐adjusted median OS (24.6 vs. 25.8 months; hazard ratio [HR] 1.13; 95% confidence interval [CI], 1.03–1.23), treatment duration (7.9 vs. 9.5 months; HR 1.21; 95% CI, 1.11–1.31), and time to subsequent therapy (14.7 vs. 17.9 months; HR 1.20; 95% CI, 1.08–1.32) were shorter with abiraterone versus enzalutamide. Among the 40% with no subsequent treatment ( n = 1102), sIPTW‐adjusted median OS (14.0 vs. 17.7 months; HR 1.32; 95% CI, 1.14–1.53), and treatment duration (7.5 vs. 10.6 months; HR 1.30; 95% CI, 1.12–1.50) were also shorter with abiraterone versus enzalutamide.

Conclusions

Using more detailed data abstraction, these results confirm prior claims‐based analyses showing that despite early use of subsequent therapy, first‐line abiraterone is associated with shorter OS versus enzalutamide in ARPI‐ and chemotherapy‐naïve mCRPC. Trial Registration Clinical Trial ID: NCT05968599

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Abiraterone AcetateAntineoplastic Combined Chemotherapy ProtocolsBenzamidesNitrilesPhenylthiohydantoinProstatic Neoplasms, Castration-ResistantAgedHumansMaleMiddle AgedDatabases, FactualElectronic Health RecordsKaplan-Meier EstimateNeoplasm Metastasis

Stichwörter der Autor:innen

abirateroneandrogen receptor pathway inhibitor‐naïvechemotherapy‐naïveenzalutamidemetastatic castration‐resistant prostate canceroverall survivalreal‐world study

Substanzen

Abiraterone AcetateBenzamidesenzalutamideNitrilesPhenylthiohydantoin

Autor:innen und Institutionen

  • Duke Cancer Institute, Durham, North Carolina, USA.
  • Pfizer Inc., New York, New York, USA.
  • Astellas Pharma Inc., Northbrook, Illinois, USA.
  • Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Durham VA Medical Center, Durham, North Carolina, USA.

ORCID-Profile: Daniel J George, Stephen J Freedland

Förderung

  • Astellas Pharma US
  • Pfizer

Zitieren

APA

George, D. J., Ivanova, J. I., Touya, M., Thompson, B., Assayag, J., Li, B., Kountouris, N., Siu, G., & Freedland, S. J. (2026). Real‐World Overall Survival With Abiraterone Acetate and Enzalutamide in Patients With Chemotherapy‐Naïve Metastatic Castration‐Resistant Prostate Cancer From the Flatiron Electronic Health Records Database. Cancer Medicine. https://doi.org/10.1002/cam4.72356

Vancouver

George DJ, Ivanova JI, Touya M, Thompson B, Assayag J, Li B, et al. Real‐World Overall Survival With Abiraterone Acetate and Enzalutamide in Patients With Chemotherapy‐Naïve Metastatic Castration‐Resistant Prostate Cancer From the Flatiron Electronic Health Records Database. Cancer Medicine. 2026. doi:10.1002/cam4.72356

BibTeX
@article{George2026,
  author = {George, Daniel J and Ivanova, Jasmina I and Touya, Maëlys and Thompson, Betty and Assayag, Jonathan and Li, Benjamin and Kountouris, Nikolaos and Siu, Gordon and Freedland, Stephen J},
  title = {Real‐World Overall Survival With Abiraterone Acetate and Enzalutamide in Patients With Chemotherapy‐Naïve Metastatic Castration‐Resistant Prostate Cancer From the Flatiron Electronic Health Records Database},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.72356}
}
Kostenlos starten →